| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Molecular Medicine |
From the Department of Medicine (B.Y., S.K., J.-L.P., N.A., J.M., N.-Q.S.) and School of Pharmacy (J.S.), University of Wisconsin, Madison; and Department of Medicine (E.M.), University of Chicago, Ill.
Correspondence to Nian-Qing Shi, PhD, Department of Medicine, University of Wisconsin, 1300, University Ave, Madison, WI 53706. E-mail nqs{at}medicine.wisc.edu
| Abstract |
|---|
|
|
|---|
Objective: We hypothesized that the mitoKATP channel contains a sulfonylurea receptor (SUR)2 regulatory subunit and aimed to identify the molecular structure.
Methods and Results: Western blot analysis in cardiac mitochondria detected a 55-kDa mitochondrial SUR2 (mitoSUR2) short form, 2 additional short forms (28 and 68 kDa), and a 130-kDa long form. RACE (Rapid Amplification of cDNA Ends) identified a 1.5-Kb transcript, which was generated by a nonconventional intraexonic splicing (IES) event within the 4th and 29th exons of the SUR2 mRNA. The translated product matched the predicted size of the 55-kDa short form. In a knockout mouse (SUR2KO), in which the SUR2 gene was disrupted, the 130-kDa mitoSUR2 was absent, but the short forms remained expressed. Diazoxide failed to induce increased fluorescence of flavoprotein oxidation in SUR2KO cells, indicating that the diazoxide-sensitive mitoKATP channel activity was associated with 130-kDa–based channels. However, SUR2KO mice displayed similar infarct sizes to preconditioned wild type, suggesting a protective role for the remaining short form-based channels. Heterologous coexpression of the SUR2 IES variant and Kir6.2 in a K+ transport mutant Escherichia coli strain permitted improved cell growth under acidic pH conditions. The SUR2 IES variant was localized to mitochondria, and removal of a predicted mitochondrial targeting sequence allowed surface expression and detection of an ATP-sensitive current when coexpressed with Kir6.2.
Conclusions: We identify a novel SUR2 IES variant in cardiac mitochondria and provide evidence that the variant-based channel can form an ATP-sensitive conductance and may contribute to cardioprotection.
Key Words: KATP channel SUR2 ischemia intraexonic splicing mitochondria
| Introduction |
|---|
|
|
|---|
In addition to a sarcolemmal location,13 the KATP channel is present in the inner membrane of mitochondria (mitoKATP).14 Both forms of channels are involved in cardioprotective pathways,15 but earlier pharmacological evidence suggests that the mitoKATP channel is more critical in conferring protection.16,17 However, the molecular composition of the mitoKATP channel is uncertain, hampering present efforts in elucidating its role in preconditioning signaling.18 Putative mitoKATP channel subunits in the sizes of 55 and 63 kDa have been enriched using an ATP-affinity chromatography method, followed by a KATP channel activity assay in reconstituted lipid bilayers.19,20 The sequences and nature of these proteins, however, remain unresolved.
In this report, we identified transcripts encoding mitochondrial-specific SUR2 (mitoSUR2) 55-kDa A and B forms, with alternative C termini. Isolation of transcripts encoding the 55-kDa forms revealed a nonconventional intraexonic splicing (IES) event, which occurred in the SUR2 mRNA to generate such variants. Further investigation suggested that modified channels formed by these IES variants generate a distinct ATP-sensitive current.
|
| Methods |
|---|
|
|
|---|
Cloning of SUR2 IES Variants
The GenBank accession numbers for SUR2A-55 and SUR2B-55 are DQ991969 and DQ991970, respectively. RACE (Rapid Amplification of cDNA Ends) and exonic polymerase chain reaction (PCR) were performed using a mouse or human heart FirstChoice RACE-Ready cDNA library (Amnion, Austin, Tex). Human LV RNA was obtained from Biochain (Hayward, Calif). Mouse heart RNA was extracted using the TRIzol reagent (Invitrogen, Carlsbad, Calif). RT-PCRs were carried out using a SuperScript RTIII kit (Invitrogen).
SUR2 Knockout Mice
Mouse protocols were performed following the guidelines of NIH at the University of Wisconsin Animal Core Facility. Heterologous SUR2 knockout (SUR2KO) mice in the FVB background were interbred and genotyped to obtain homozygous mutants.21 Age-matched homozygous wild-type (WT) and KO littermates were used in this study.
Related Antibodies
SUR2-specific antibodies were generated as previously described.10 Anti-Na+/K+ ATPase, anti-VDAC1, and anti-COXIV were from Cell Signaling Technology (Danvers, Mass). Secondary antibodies were from GE Healthcare (Piscataway, NJ).
Isolation of Mitochondrial Fractions
Progressive isolation of heart22,23 or brain24 mitochondrial membranes was performed as previously described with modifications.
Flavoprotein Fluorescence and Electrophysiological Recordings
Ventricular myocytes were isolated25 from 10-week-old mice for fluorescence measurement of flavoprotein oxidation.26 Diazoxide, 5-hydroxydecanoate, dinitrophenol, or pinacidil was added at 100 µmol/L, 500 µmol/L, 100 µmol/L, or 100 µmol/L, respectively. KATP current (IKATP) was recorded as previously described.10
Escherichia coli Cell Growth Experiments
MG1655 was provided by the University of Wisconsin E coli Sequencing Project.27 ME6106 (kdpABC5, trkA) was obtained from The Japanese National BioResource Project.28 Each SUR2 IES variant or a full-length SUR2A cDNA was subcloned into pcDNA3 (Invitrogen) as pNQ55, pNQ64, and pSUR2A. A mouse Kir6.2 plasmid was obtained as previously described.10
Mitochondrial Localization and Current Recording
Each SUR2 IES variant was subcloned into a bicistronic pGFPIRS vector (a kind gift from David Johns, Johns Hopkins University, Baltimore, Md) as pNQ66 or pNQ67 for mitochondrial localization. Green fluorescent protein (GFP) that was fused to a known mitochondrial targeting sequence (MTS) in a eukaryotic expression vector (Clonetech, Valencia, Calif) was used as a control. Each plasmid was transfected into COS1 cells, and the transfected cells were stained with MitoTracker (Invitrogen) 24 hours posttransfection. The cells were then scanned with a confocal microscope (Bio-Rad, Hercules, Calif) and analyzed subsequently. The putative MTS for the SUR2 IES variants was removed by mutagenesis. A MTS-less SUR2B-55 or the full-length SUR2A was subcloned into pGFPIRS as pNQ62 or pNQ69. Each plasmid was transfected in a Kir6.2 stable COS1 line.10 A vector control was also transfected. IKATP or ATP sensitivity (100 µmol/L) was recorded as previously described.10
Ischemia and Ischemic Preconditioning
Ischemia/reperfusion, ischemic preconditioning (IPC), and infarct size determination were operated as previously described.29–31
Statistical Analysis
Data are reported as means±SEM in the ischemia experiments and as means±SD in the cell growth experiments. A Students t test or 2-way ANOVA was performed where appropriate, with P<0.05 considered significant.
| Results |
|---|
|
|
|---|
|
Identification of the SUR2 IES Variants
DNA sequences encoding the mitoSUR2 short forms were sought in a mouse heart cDNA library using 5' or 3' RACEs, and the variants were amplified subsequently by nested exonic PCR (Figure 2A and 2B). A 1.5-Kb band was obtained in addition to a 4.6-Kb SUR2 band (Figure 2C). Cloning and sequencing of the 1.5-Kb transcripts revealed that they resulted from a nonconventional IES, which occurred within exons 4 and 29 of the SUR2 mRNA (Figure 2B). Each IES variant contained 13 exons encoding a 55-kDa protein. PCR with primer P4, which spans the IES junction of exons 4 and 29 of SUR2, detected an expected 1.1-Kb band (Figure 2C), confirming the existence of an IES junction that was not present in SUR2 conventional splice variants. To ensure that IES did occur in isolated SUR2 mRNA, primer P5, located just before the IES junction, was designed. RT-PCR with P5 using isolated WT mouse heart mRNA detected a 4.2-Kb band, suggesting that P5 annealed to SUR2 conventional variants as templates. A 1.1-Kb band was also obtained indicating that P5 could anneal to the SUR2 IES variants as templates. The results suggested that the IES variants coexisted with SUR2 conventional splice variants.
|
Because significant homologies between the human and mouse SUR2 conventional splice variants at the nucleic acid level have been reported,8,9 the same approach was used to amplify the 1.5-Kb IES variants from a human heart cDNA library (Figure 2D). PCRs using P4/h2 or P4/h3 detected an expected 1.1-Kb band. Moreover, an expected 1.1-Kb RT-PCR band using primers P4/h2 or P4/h3 was detected in mRNA isolated from human heart tissues. Because it was relatively easier to characterize functions of the IES variants using SUR2KO mice, we focused on the mouse variants in subsequent studies.
Regulation of SUR2 IES Variant Expression
When cloning the transcripts encoding the SUR2 IES variants, we found both "in-frame" and "out-of-frame" products in WT mouse hearts. The out-of-frame product lacked a "G" at the IES junction region between exons 4 and 29 (Figure 3A). The extra G abolished the IES event, resulting in a 510-bp short transcript encoding a 20-kDa protein (Figure 3B). However, the G was present in the in-frame 1464-bp transcript, which encodes a 55-kDa protein. Our observations suggested that IES splicing could be controlled in cardiac cells.
|
Expression levels of both IES variants were compared in WT mice at 3, 10, or 50 weeks of age by a quantitative RT-PCR (Figure 3C). IES variant expression in the 3-week-old group was significantly higher than that in the 10- or 50-week-old group, suggesting that SUR2 IES variant expression decreased with aging.
The IES Variants are "Undisturbed" in SUR2KO mice
SUR2KO mice were previously generated by inserting a disruption cassette between exons 12 to 16 of the SUR2 cDNA (Figure 4A).32 RT-PCRs were carried out using mRNA isolated from the SUR2KO hearts and detected presence of SUR2 IES variants (Figure 4B and 4C). The 1.1-Kb bands encoding the 55-kDa forms were detected, cloned, and confirmed by sequencing. SUR2-specific antibodies were used to cross-react with SUR2KO cardiac mitochondrial samples (Figure 4D). Neither T1 nor BNJ-2 detected any signal in the mutant, suggesting that the 130-kDa mitoSUR2 long form was disrupted. However, BNJ-39 and BNJ-40 still detected the mitoSUR2 short forms. The results indicated that mitoSUR2 short forms remained expressed in SUR2KO cardiac mitochondria. We reasoned that the transcripts encoding SUR2 IES variants were unaffected in the mutant because IES occurred within exons 4 and 29, bypassing the targeted disruption site.
|
Flavoprotein Oxidation in SUR2KO Cells
Flavoprotein oxidation26 was used to characterize whether the diazoxide-induced mitoKATP channel activity was intact in SUR2KO cells (Figure 5A and 5B). In the presence of diazoxide, fluorescence resulted from flavoprotein oxidation was significantly enhanced in WT cells. By contrast, diazoxide failed to elicit increased fluorescence in SUR2KO cells, suggesting that the diazoxide-sensitive mitoKATP channel activity was absent. To ensure that diazoxide acted at the level of the mitoKATP channel but not the sarcKATP channel, IKATP was recorded from the isolated cells in parallel (Figure 5C and 5D). Diazoxide did not activate IKATP in WT or SUR2KO cells, whereas pinacidil-induced IKATP was recorded from WT cells. Because the 130-kDa mitoSUR2 (SUR2–130) was disrupted in SUR2KO mice, these results are consistent with the presence of a mitoKATP channel and the notion that the diazoxide-sensitive mitoKATP channel activity may be associated with SUR2–130.
|
Heterologous Expression of SUR2 IES Variants
Mitochondria and bacteria possess similar protein synthesizing machinery, and bacteria cannot recognize a mitochondrial targeting sequence, so they are frequently used to express mitochondrial proteins. Potassium transport is a fundamental requirement for maintaining pH homeostasis in bacteria and 3 potassium uptake systems exist in bacteria. An E coli mutant ME6106 that lacks both kdpABC and trkA systems relies on the remaining kup system for growth.33 The kup system specifically supports cell growth under low pH conditions. When grown at pH 5.5 in the presence of glucose, this mutant extrudes H+ in exchange for K+.34 We hypothesized that an introduced potassium transport machinery could improve cell growth in ME6106. It is known that acidic pH conditions activate KATP channels.35 Modulation of KATP channel activities by pH is mainly through Kir6.2,36 but recent evidence suggests that SUR2 is involved in regulating Kir6.2 under low pH conditions.37 We tested whether coexpression of each IES variant with Kir6.2 could enhance cell growth of ME6106 at pH 5.5 (Figure 6A). ME6106 was transformed with Kir6.2 plus SUR2–55A, SUR2–55B, SUR2A, or the empty vector. All positive transformants, the untransformed ME6106, and an untransformed WT E coli K12 strain, MG1655, were tested for growth at pH 5.5. MG1655 (blue) stopped growing as expected when pH in the medium dropped to 2.2. The untransformed ME6106 (orange) grew relatively slower than MG1655 at the beginning as reported, but it continued to grow during the testing period. ME6106 containing Kir6.2/vector (green) showed a significantly 10% higher growth than the untransformed ME6106, suggesting that the expressed Kir6.2 could improve growth in ME6106. ME6106 containing Kir6.2/SUR2–55A (pink), Kir6.2/SUR2–55B (cyan), or Kir6.2/SUR2A (red) displayed a significantly 18%, 19%, or 27% higher cell growth than ME6106. Our results supported a regulatory role for the SUR2 IES variants to Kir6.2, but the full-length SUR2A had a stronger effect relative to the SUR2 IES variants.
|
Mitochondrial Localization of the SUR2 IES Variants
We further tested whether heterologously expressed SUR2 IES variants could be targeted to mitochondria. Each SUR2 IES variant–GFP fusion or a mitochondrial green fluorescent protein (mitoGFP) control was transiently transfected into COS1 cells and imaged by confocal scanning. Green fluorescence distribution of each expressed target, MitoTracker Red labeling, and the overlay images were recorded (Figure 6B). Like the positive control mitoGFP, green signals in the SUR2 IES variant–GFP fusions overlapped with MitoTracker staining, suggesting that both variants were localized to mitochondria.
Protein import into mitochondria generally requires a N-terminal cleavable MTS that normally contains 20 to 30 amino acids, but the length can be longer in some cases.38 Deleting MTS is expected to allow a mitochondrial protein to be expressed on cell surface for further functional study, such as voltage clamping.39 However, some MTS motifs are noncleavable; therefore, they remain intact as part of the mature proteins.38 Although consensus for each type of MTS has been reported, a functional test is ultimately required to either demonstrate mitochondrial expression by fusing the putative motif to a known nonmitochondrial protein or to show nonmitochondrial expression after removing the putative MTS. We hypothesized that a MTS is present in the N terminus of SUR2 IES variants, and removal of it could lead to nonmitochondrial expression. This putative MTS, which contains the first 30 amino acids of SUR2 IES variants, was deleted by mutagenesis. Each MTS-less SUR2 IES variant–GFP fusion was transiently transfected into COS1 cells for confocal imaging (Figure 7A). The detected green signal and MitoTracker staining did not overlap in the modified SUR2 IES variants, indicating that the mitochondrial expression was altered. We also observed some aggregated MTS-less SUR2 IES variant signal (ie, the green panel for MTS-less SUR2A-55), suggesting that some proteins may not traffic properly to cell surface as previously reported.39
|
Characterization of a Recombinant Channel of MTS-Less SUR2B-55/Kir6.2
To confirm that cell surface expression was achieved in the MTS-less SUR2 IES variants, K+ currents were recorded from a modified SUR2B-55 IES variant–based channel by expressing the mutant variant into a Kir6.2 stable COS1 line. Currents were recorded from the recombinant channel, whereas no currents were detected from the vector control in the absence of glibenclamide (Figure 7B). Unlike the glibenclamide-sensitive current detected from the SUR2A/Kir6.2 channel, the MTS-less variant-based channel had a smaller amplitude and displayed insensitivity to glibenclamide (Figure 7C). The current had kinetics and conductance typical of IKATP and was inhibited by 100 µmol/L ATP (Figure 7D). Our data demonstrated that the recombinant channel conferred an ATP-sensitive IKATP activity.
Ischemic Protection in SUR2KO Mice
We evaluated ischemic protection in SUR2KO mice, in which the mitoSUR2 short forms remained expressed. In the ischemia/reperfusion experiment, mice were subjected to 30-minute ischemia and 24-hour reperfusion. The average infarct sizes of preconditioned hearts in WT mice (27%) were significantly reduced relative to the ischemic hearts (45%), suggesting that our protocols were effective (Figure 8A). As observed previously,40 SUR2KO mice (24%) displayed significantly smaller infarcts than WT (45%) in ischemia, suggesting that they were less susceptible to ischemic/reperfusion injuries. IPC significantly limited infarcts in WT mice (27%), but it did not allow significant further improvement in SUR2KO mice (21%). The average infarct sizes recorded from the ischemic SUR2KO hearts were comparable to in the preconditioned WT hearts, suggesting that the SUR2KO mice were "constitutively" engaged in a protected state without preconditioning after losing the 130-kDa mitoSUR2.
|
| Discussion |
|---|
|
|
|---|
Transcripts encoding the 55-kDa mitoSUR2 short forms were found to be products of a nonconventional IES event,43 which occurred within the 4th and the 29th exons of the SUR2 mRNA. Based on the sequence information, we noticed that the SUR2 IES variants are 100% identical to the SUR2 conventional splice variants at the protein level, except the truncated transmembrane helix5–16. Therefore, attempts using SUR2-specific antibodies to immunoprecipitate a purified mitochondrial fraction for mass spectrometry might not identify these variants because the resultant hits could be considered as partial sequences of those SUR2 conventional splice variants. The copresence of various types of SUR2 splice variants may have hindered the progress of other protein-based efforts in the past.
In contrast to conventional splicing that occurs between an exon and an intron, IES takes place within 2 exons, leading to shorter but in-frame variants.43 To date, approximately 10 cases of IES events have been reported in mammalian genes, mostly under disease conditions.44 This is the first report of finding an IES event in an ATP-binding cassette (ABC) transporter and a mammalian ion channel. Because of the rarity of IES, mechanisms that generate these IES variants are not fully understood. It is thought that recognition of the IES junction is influenced by 2 major factors, assembly of a spliceosome complex and quantitative scanning of the target sequence from a transcriptional/splicing machinery complex primed by upstream splicing signals. Previous results have shown that a typical 5' IES donor site has a nAG/GTnnnn consensus, whereas a 3' IES acceptor site has a frequent CAG/G motif.45 We found nnG/GTnnnn as the 5' donor site and nAG/G as the 3' acceptor site for SUR2 IES variants, which matched the consensus motifs. In this work, we also found that IES splicing can be controlled and regulated in cardiac cells.
SURs belong to the ABC transporter superfamily.46 Traditional ABC transporters have 2 transmembrane domains (TMDs) and 2 symmetrical nucleotide-binding domains (NBDs). SURs do not play transport functions and differ from other ABC transporters by possessing an additional TMD and 2 asymmetrical NBDs. Hemi-ABC transporters have been described to use their single TMD to receive regulatory signals from the only NBD,47 and they are found in mitochondria.48 The identified SUR2 IES variants lack TMD1 and NBD1, but they have an intact NBD2 and a new hybrid TMD (Figure 8B). The SUR2 IES variant–based channels are expected to be relatively insensitive to most sulfonylureas based on the deduced topology. We provided evidence that the modified SUR2B-55 IES variant and Kir6.2 form an KATP channels (Figure 7B through 7D). The SUR2 IES variants can regulate Kir6.2 activity and support better growth under acidic pH conditions (Figure 6A). These results suggest that the SUR2 IES variants may function as hemi-ABC transporters. It is unclear how the SUR2A-68 and SUR2A-28 variants remain expressed in SUR2KO mice, but we demonstrated that the 55-kDa variants were unaffected because of the IES event. IES may serve as a mechanism to retain certain level of mitoKATP channel activity in cardiac cells.
Results from the flavoprotein oxidation experiment suggest that SUR2KO mice lacked the diazoxide-sensitive mitoKATP channel activity found in WT. This finding differs from a previously reported Kir6.2 KO, where the diazoxide-sensitive mitoKATP channel activity is comparable to the WT controls.49 Our observation provides evidence that the diazoxide-sensitive florescence could be associated with a distinct SUR2–130–based mitoKATP channel. IPC study showed that the recorded infarcts in SUR2KO mice, where the mitoSUR2 short forms remained expressed, is similar to preconditioned WT, suggesting that the mutant mice were protected. The SUR2–130–based channels may not be required for conferring protection itself as the mutant mice lacking the long form are constitutively protected in ischemia. Future pharmacological study in the mitoKATP channel conductance formed by both the long and short mitoSUR2 forms will be evaluated to interpret their roles in preconditioning.
In summary, we have characterized the sequence and function of SUR2 IES variants in cardiac mitochondria and provided evidence that it forms a KATP channel when the MTS is removed. Future studies in the pharmacology and pathophysiology of channels constituted by these forms may provide new insights into the cardioprotective pathway.
| Acknowledgments |
|---|
This study was supported by American Heart Association National Center Grants 0630268N (to N.-Q.S.) and 0435030N (to B.Y.) and NIH grants R01HL-57414 (to J.M.) and R01 HL078926 (to E.M.).
Disclosures
None.
| Footnotes |
|---|
Original received January 31, 2009; revision received August 28, 2009; accepted September 23, 2009.
| References |
|---|
|
|
|---|
2. Thanaraj TA, Stamm S. Prediction and statistical analysis of alternatively spliced exons. Prog Mol Subcell Biol. 2003; 31: 1–31.[Medline] [Order article via Infotrieve]
3. Clement JP, Kunjilwar K, Gonzalez G, Schwanstecher M, Panten U, Aguilar-Bryan L, Bryan J. Association and stoichiometry of K(ATP) channel subunits. Neuron. 1997; 18: 827–838.[CrossRef][Medline] [Order article via Infotrieve]
4. Aguilar-Bryan L, Clement JP, Gonzalez G, Kunjilwar K, Babenko A, Bryan J. Toward understanding the assembly and structure of KATP channels. Physiol Rev. 1998; 78: 227–245.
5. Shi NQ, Ye B, Makielski JC. Function and distribution of the SUR isoforms and splice variants. J Mol Cell Cardiol. 2005; 39: 51–60.[CrossRef][Medline] [Order article via Infotrieve]
6. Inagaki N, Gonoi T, Clement JP, Wang CZ, Aguilar-Bryan L, Bryan J, Seino S. A family of sulfonylurea receptors determines the pharmacological properties of ATP-sensitive K+ channels. Neuron. 1996; 16: 1011–1017.[CrossRef][Medline] [Order article via Infotrieve]
7. Chutkow WA, Simon MC, Le Beau MM, Burant CF. Cloning, tissue expression, and chromosomal localization of SUR2, the putative drug-binding subunit of cardiac, skeletal muscle, and vascular KATP channels. Diabetes. 1996; 45: 1439–1445.[Abstract]
8. Chutkow WA, Makielski JC, Nelson DJ, Burant CF, Fan Z. Alternative splicing of SUR2 Exon 17 regulates nucleotide sensitivity of the ATP-sensitive potassium channel. J Biol Chem. 1999; 274: 13656–13665.
9. Davis-Taber R, Choi W, Feng J, Hoogenboom L, McNally T, Kroeger P, Shieh C, Simmer R, Brioni J, Sullivan J, Gopalakrishnan M, Scott V. Molecular characterization of human SUR2-containing K(ATP) channels. Gene. 2000; 256: 261–270.[CrossRef][Medline] [Order article via Infotrieve]
10. Pu JL, Ye B, Kroboth SL, McNally EM, Makielski JC, Shi NQ. Cardiac SUR short form-based channels confer a glibenclamide-insensitive KATP activity. J Mol Cell Cardiol. 2008; 44: 188–200.[CrossRef][Medline] [Order article via Infotrieve]
11. Kramer W, Ökonomopulos R, Punter J, Summ HD. Direct photoaffinity labeling of the putative sulfonylurea receptor in rat beta-cell tumor membranes by [3H]glibenclamide. FEBS Lett. 1988; 229: 355–359.[CrossRef][Medline] [Order article via Infotrieve]
12. Kramer W, Muller G, Girbig F, Gutjahr U, Kowalewski S, Hartz D, Summ HD. Differential interaction of glimepiride and glibenclamide with the beta-cell sulfonylurea receptor. II. Photo-affinity labeling of a 65-kDa protein by [3H]glimepiride. Biochim Biophys Acta. 1994; 1191: 278–290.[Medline] [Order article via Infotrieve]
13. Noma A. ATP-regulated K+ channels in cardiac muscle. Nature. 1983; 305: 147–148.[CrossRef][Medline] [Order article via Infotrieve]
14. Inoue I, Nagase H, Kishi K, Higuti T. ATP-sensitive K+ channel in the mitochondrial inner membrane. Nature. 1991; 352: 244–247.[CrossRef][Medline] [Order article via Infotrieve]
15. Murry CE, Jennings RB, Reimer KA. Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium. Circulation. 1986; 74: 1124–1136.
16. Garlid KD, Paucek P, Yarov-Yarovoy V, Sun X, Schindler PA. The mitochondrial KATP channel as a receptor for potassium channel openers. J Biol Chem. 1996; 271: 8796–8799.
17. Garlid KD, Paucek P, Yarov-Yarovoy V, Murray HN, Darbenzio RB, D'Alonzo AJ, Lodge NJ, Smith MA, Grover GJ. Cardioprotective effect of diazoxide and its interaction with mitochondrial ATP- sensitive K+ channels. Possible mechanism of cardioprotection. Circ Res. 1997; 81: 1072–1082.
18. O'Rourke B. Evidence for mitochondrial K+ channels and their role in cardioprotection. Circ Res. 2004; 94: 420–432.
19. Mironova GD, Fedotcheva NI, Makarov PR, Pronevich LA, Mironov GP. Protein from beef heart mitochondria inducing the potassium channel conductivity of bilayer lipid membrane. Biofizika. 1981; 26: 451–457.[Medline] [Order article via Infotrieve]
20. Paucek P, Mironova G, Mahdi F, Beavis AD, Woldegiorgis G, Garlid KD. Reconstitution and partial purification of the glibenclamide-sensitive, ATP-dependent K+ channel from rat liver and beef heart mitochondria. J Biol Chem. 1992; 267: 26062–26069.
21. Kakkar R, Ye B, Stoller DA, Smelley M, Shi NQ, Galles K, Hadhazy M, Makielski JC, McNally EM. Spontaneous coronary vasospasm in KATP mutant mice arises from a smooth muscle-extrinsic process. Circ Res. 2006; 98: 675–689.
22. Greenawalt JW. The isolation of outer and inner mitochondrial membranes. Methods Enzymol. 1974; 31: 310–323.[Medline] [Order article via Infotrieve]
23. Jacobs EE, Sanadi DR. The removal of cytochrome c from mitochondria. J Biol Chem. 1960; 235: 531–534.
24. Anderson MF, Sims NR. Improved recovery of highly enriched mitochondrial fractions from small brain tissues samples. Brain Res Brain Res Protoc. 2000; 5: 95–101.[CrossRef][Medline] [Order article via Infotrieve]
25. Wolska BM, Solaro RJ. Method for isolation of adult mouse cardiac myocytes for studies of contraction and micro-fluorimetry. Am J Physiol. 1996; 271: H1250–H1255.[Medline] [Order article via Infotrieve]
26. Liu YG, Sato T, O'Rourke B, Marban E. Mitochondrial ATP-depedent potassium channels-novel effectors of cardioprotection? Circulation. 1998; 97: 2463–2469.
27. Blattner FR, Plunkett G III, Bloch CA, Perna NT, Burland V, Riley M, Collado-Vides J, Glasner JD, Rode CK, Mayhew GF, Gregor J, Davis NW, Kirkpatrick HA, Goeden MA, Rose DJ, Mau B, Shao Y. The complete genome sequence of Escherichia coli K-12. Science. 1997; 277: 1453–1474.
28. Baba T, Ara T, Hasegawa M, Takai Y, Okumura Y, Baba M, Datsenko KA, Tomita M, Wanner BL Mori H. Construction of Escherichia coli K-12 in-frame, single-gene knockout mutants: the Keio collection. Mol Sys Biol. 2006; 2: 1–11.
29. Ockaili R, Emani V, Okubo S, Brown M, Krottapalli K, Kukreja R. Opening of mitochondrial KATP channel induces early and delayed cardioprotective effect: role of nitric oxide. Am J Physiol. 1999; 277: H2425–H2434.[Medline] [Order article via Infotrieve]
30. Guo Y, Wu WJ, Qiu Y, Tang XL, Yang Z, Bolli R. Demonstration of an early and a late phase of ischemic preconditioning in mice. Am J Physiol. 1998; 75: H1375–H1387.
31. Ytrehus K, Liu Y, Tsuchida A, Miura T, Liu GS, Yang X, Herbert D, Cohen MV, Downey JM. Rat and rabbit heart infarction: effects of anesthesia, perfusate, risk zone, and method of infarct sizing. Am J Physiol. 1994; 267: H2383–H2390.[Medline] [Order article via Infotrieve]
32. Chutkow WA, Samuel V, Hansen PA, Pu JL, Valdivia CR, Makielski JC, Burant CF. Disruption of Sur2-containing KATP channels enhances insulin-stimulated glucose uptake in skeletal muscle. Proc Natl Acad Sci U S A. 2001; 98: 11760–11764.
33. Trchounian A, Kobayashi H. Kup is the major K+ uptake system in Escherichia coli upon hyper- osmotic stress at a low pH. FEBS Lett. 1999; 447: 144–148.[CrossRef][Medline] [Order article via Infotrieve]
34. Zakharyan E, Trchounian A. K+ flux by Kup in Escherichia coli is accompanied by a decrease in H+ flux. FEMS Microbiol Lett. 2001; 204: 61–64.[CrossRef][Medline] [Order article via Infotrieve]
35. Fan Z, Makielski JC. Intracellular H+ and Ca2+ modulation of trypsin-modified ATP-sensitive K+ channels in rabbit ventricular myocytes. Circ Res. 1993; 72: 715–722.
36. Xu H, Cui N, Yang Z, Wu J, Giwa LR, Abdulkadir L, Sharma P, Jiang C. Direct activation of cloned K(atp) channels by intracellular acidosis. J Biol Chem. 2001; 276: 12989–12902.
37. Wu J, Cui N, Piao H, Wang Y, Xu H, Mao J, Jiang C. Allosteric modulation of the mouse Kir6.2 channel by intracellular H+ and ATP. J Physiol. 2002; 543: 495–504.
38. Mokranjac D, Neupert W. Thirty years of protein translocation into mitochondria: unexpectedly complex and still puzzling. Biochim Biophys Acta. 2009; 1793: 33–41.[Medline] [Order article via Infotrieve]
39. Ardehali H, Xue T, Dong PH, Machamer C. Targeting of the mitochondrial membrane proteins to the cell surface for functional studies. Biochem Biophys Res Commum. 2005; 338: 1143–1151.[CrossRef][Medline] [Order article via Infotrieve]
40. Stoller D, Kakkar R, Smelley M, Chalupsky K, Earley JU, Shi NQ, Makielski JC, McNally EM. Mice lacking sulfonylurea receptor 2 ATP sensitive potassium channels are resistant to acute cardiovascular stress. J Mol Cell Cardiol. 2007; 43: 445–454.[CrossRef][Medline] [Order article via Infotrieve]
41. Mironova GD, Negoda AE, Marinov BS, Paucek P, Costa AD, Grigoriev SM, Skarga YY, Garlid KD. Functional distinctions between the mitochondrial ATP-dependent K+ channel (mitoKATP) and its inward rectifier subunit (mitoKIR). J Biol Chem. 2004; 279: 32562–32568.
42. Foster DB, Rucker JJ, Marban E. Is Kir6.1 a subunit of mitoKATP? Biochem Biophys Res Commun. 2008; 366: 649–656.[CrossRef][Medline] [Order article via Infotrieve]
43. Uinuk-Ool T, Nikolaidis N, Sato A, Mayer WE, Klein J. Organization, alternative splicing, polymorphism, and phylogenetic position of lamprey CD45 gene. Immunogenetics. 2005; 57: 607–617.[CrossRef][Medline] [Order article via Infotrieve]
44. Saad FA, Vitiello L, Merlini L, Mostacciuolo ML, Oliviero S, Danieli GA. A 3' consensus splice mutation in the human dystrophin gene detected by a screening for intra-exonic deletions. Hum Mol Genet. 1992; 1: 345–346.
45. Romano M, Marcucci R, Baralle FE. Splicing of constitutive upstream introns is essential for the recognition of intra-exonic suboptimal splice sites in the thrombopoietin gene. Nucleic Acids Res. 2001; 29: 886–894.
46. Dean M, Rzhetsky A, Allikmets R. The human ATP-binding cassette transporter superfamily. Genome Res. 2001; 11: 1156–1166.
47. Hyde SC, Emsley P, Hartshorn MJ, Mimmack MM, Gileadi U, Pearce SR, Gallagher MP, Gill DR, Hubbard RE, Higgins CF. Structural model of ATP-binding proteins associated with cystic fibrosis, multidrug resistance and bacterial transport. Nature. 1990; 346: 362–365.[CrossRef][Medline] [Order article via Infotrieve]
48. Graf SA, Haigh SE, Corson E, Shirihai OS. Targeting, import, and dimerization of a mammalian mitochondrial ATP binding cassette (ABC) transporter, ABCB10 (ABC-me). J Biol Chem. 2004; 279: 42954–42963.
49. Suzuki M, Sasaki N, Miki T, Sakamoto N, Ohmoto-Sekine Y, Tamagawa M, Seino S, Marban E, Nakaya H. Role of sarcolemmal KATP channels in cardioprotection against ischemia/reperfusion injury in mice. J Clin Invest. 2002; 109: 509–516.[CrossRef][Medline] [Order article via Infotrieve]
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Circulation Research Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2009 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |